| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8735298 | Hepatobiliary & Pancreatic Diseases International | 2017 | 6 Pages |
Abstract
TACE is a more cost-effective strategy than TACE-sorafenib for the treatment of unresectable HCC.
Related Topics
Health Sciences
Medicine and Dentistry
Hepatology
Authors
Rong-Ce Zhao, Jing Zhou, Yong-Gang Wei, Fei Liu, Ke-Fei Chen, Qiu Li, Bo Li,